| Literature DB >> 25975961 |
Sloane McGraw1, Omer Mirza1, Michael A Bauml1, Vibhav S Rangarajan1, Afshin Farzaneh-Far2,3.
Abstract
BACKGROUND: Appropriate use criteria (AUC) have been developed by professional organizations as a response to the rising costs of imaging, with the goal of optimizing test-patient selection. Consequently, the AUC are now increasingly used by third-party-payers to assess reimbursement. However, these criteria were created by expert consensus and have not been systematically assessed for CMR. The aim of this study was to determine the rates of abnormal stress-CMR and subsequent downstream utilization of angiography and revascularization procedures based on the most recent AUC.Entities:
Mesh:
Year: 2015 PMID: 25975961 PMCID: PMC4432497 DOI: 10.1186/s12968-015-0137-x
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Baseline Characteristics Stratified by Appropriate Use Criteria
| CHARACTERISTICS | Total N = 300 | Appropriate N = 149 | Maybe Appropriate N = 110 | Rarely Appropriate N = 41 | P Value |
|---|---|---|---|---|---|
|
| 59 (±13.6) | 61 (±12.0) | 61 (±13.3) | 46 (±14.4) | <0.0001 |
|
| 54.0 | 49.7 | 55.0 | 66.7 | 0.1703 |
|
| 30.8 (±5.7) | 31.3 (±5.4) | 30.8 (±6.1) | 29.2 (±5.5) | 0.1000 |
|
| 36.2 | 43.6 | 32.4 | 16.7 | 0.0049 |
|
| 53.6 | 60.4 | 55.9 | 23.8 | 0.0002 |
|
| 16.3 | 18.8 | 8.5 | 27.8 | 0.0089 |
|
| 73.0 | 78.5 | 74.8 | 45.2 | 0.0002 |
|
| 32.1 | 39.6 | 29.7 | 11.9 | 0.0032 |
|
| 13.6 | 16.1 | 13.5 | 4.8 | 0.1793 |
|
| 16.9 | 22.8 | 14.4 | 2.4 | 0.0061 |
|
| 4.3 | 3.4 | 7.3 | 0 | 0.1058 |
|
| 61 (±10.9) | 60.3 (±12.0) | 61 (±10.7) | 62 (±6.8) | 0.4800 |
BMI, Body Mass Index; CAD, Coronary Artery Disease; LVEF, Left Ventricular Ejection Fraction; MI, myocardial infarction; PCI, Percutaneous Coronary Intervention; CABG, Coronary Artery Bypass Grafting; SD, standard deviation
AUC categories in our study population
| AUC Description | N | Classification |
|---|---|---|
| Follow-up testing (>90 days) for new or worsening symptoms with non-obstructive CAD on coronary angiography (invasive or noninvasive) OR normal prior stress imaging study | 48 | A |
| Symptomatic in intermediate pre-test probability of CAD with interpretable ECG AND able to exercise | 32 | M |
| Symptomatic in intermediate pre-test probability of CAD with uninterpretable ECG OR unable to exercise | 27 | A |
| Newly diagnosed systolic heart failure (resting LV function previously assessed but no prior CAD evaluation) | 25 | A |
| Evaluation for symptomatic (ischemic equivalent) post-revascularization (PCI or CABG) | 24 | A |
| Sequential or follow up testing (≤90 days) with uncertain results on prior stress imaging study (not stress CMR) where obstructive CAD remains a concern | 23 | M |
| Symptomatic in low pre-test probability of CAD with interpretable ECG AND able to exercise | 20 | R |
| Pre-operative clearance in poor or unknown functional capacity (<4 METS); intermediate risk surgery with ≥1 clinical risk factor | 12 | M |
| High pre-test probability of CAD with an interpretable ECG and able to exercise | 8 | A |
| High pre-test probability of CAD with an uninterpretable ECG and unable to exercise | 6 | A |
| Follow up testing for new or worsening symptoms with an abnormal prior stress imaging study | 6 | M |
| Follow up testing (>90 Days) in an asymptomatic or symptomatically stable patient whose last study was ≥ 2 years ago | 4 | M |
| Follow up testing (>90 Days) in an asymptomatic patient without ischemic equivalent, who has a normal prior stress imaging study or non-obstructive CAD on angiogram who is intermediate to high global CAD risk with a study ≥ 2 years ago | 4 | M |
| Follow up testing (>90 Days) in an a patient with stable symptoms, who has a normal prior stress imaging study or non-obstructive CAD on angiogram who is intermediate to high global CAD risk with a study ≥ 2 years ago | 4 | M |
| Symptomatic patients who are low pre-test probability of CAD with an uninterpretable ECG or unable to exercise | 3 | M |
| Newly diagnosed diastolic heart failure | 3 | A |
| Evaluation of arrhythmias without ischemic equivalent with frequent PVCs | 3 | M |
| Syncope without ischemic equivalent in a patient with low global CAD risk | 3 | R |
| Follow up testing (>90 Days) in an asymptomatic or symptomatically stable patient with a history of abnormal prior stress imaging study < 2 years ago | 3 | R |
| Follow up testing (>90 Days) in an asymptomatic patient with a normal prior stress imaging study OR non-obstructive CAD on angiogram | 3 | R |
| Follow up testing for new or worsening symptoms in a patient with prior obstructive CAD on invasive coronary angiography | 3 | M |
| Pre-op risk stratification in a patient with poor or unknown functional capacity (<4 METs) in a patient who is undergoing vascular surgery with ≥ 1 clinical risk factor | 3 | M |
AUC, Appropriate Use Criteria; A, Appropriate, M, Maybe Appropriate; R, Rarely Appropriate; CAD, Coronary Artery Disease; ECG, Electrocardiogram; LV, Left Ventricular; PCI, Percutaneous Coronary Intervention; CABG, Coronary Artery Bypass Grafting; PVC, Premature Ventricular Beat
Fig. 1Appropriate use criteria and stress-CMR findings in the study population
Fig. 2Studies with ischemia categorized by appropriate use criteria
Fig. 3Patients undergoing cardiac catheterization who required revascularization, categorized by appropriate use criteria